Vericel Corporation (NASDAQ:VCEL) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Vericel Corporation (NASDAQ:VCEL) has received an average rating of "Buy" from five brokerage firms, with a consensus price target of $60.40 for the next year.
• Despite a recent 4.0% decline in share price, Vericel's stock has fluctuated between $30.26 and $63.00 over the past twelve months, reflecting significant market interest.
• The company reported a 20.1% year-over-year revenue growth with earnings per share of ($0.01), surpassing analysts' expectations for the most recent quarter.

Shares of Vericel Corporation (NASDAQ:VCEL - Get Free Report) have been assigned an average rating of "Buy" from the five ratings firms that are presently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $60.40.

VCEL has been the subject of a number of research reports. Canaccord Genuity Group dropped their price objective on Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a research note on Friday, August 1st. Stephens reiterated an "overweight" rating and issued a $67.00 target price on shares of Vericel in a report on Monday, June 16th.

Vericel Trading Down 4.0%

Shares of NASDAQ VCEL opened at $32.18 on Monday. Vericel has a twelve month low of $30.26 and a twelve month high of $63.00. The stock has a fifty day simple moving average of $36.70 and a 200-day simple moving average of $40.81. The stock has a market capitalization of $1.62 billion, a PE ratio of 268.19 and a beta of 1.33.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The business had revenue of $63.24 million during the quarter, compared to analysts' expectations of $64.61 million. During the same period in the previous year, the firm posted ($0.10) earnings per share. The company's revenue was up 20.1% on a year-over-year basis. On average, equities analysts predict that Vericel will post 0.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VCEL. Ameritas Advisory Services LLC purchased a new position in Vericel in the second quarter valued at $30,000. GF Fund Management CO. LTD. purchased a new position in Vericel in the fourth quarter valued at $57,000. CWM LLC boosted its holdings in Vericel by 101.3% in the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 694 shares during the period. AlphaQuest LLC purchased a new stake in Vericel during the 2nd quarter worth about $60,000. Finally, Osaic Holdings Inc. lifted its holdings in Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company's stock worth $125,000 after buying an additional 353 shares during the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.